Preclinical Development of Kinase/Phosphatase Drugs

Preclinical Development of Kinase/Phosphatase Drugs

Home / Solutions / Kinase/Phosphatase Drug Discovery & Development / Preclinical Development of Kinase/Phosphatase Drugs

Preclinical Development of Kinase/Phosphatase Drugs


With many years of experience in drug development, Creative BioMart is committed to providing our customers with integrated solutions that are completely customer tailored for the preclinical development of kinase and phosphatase drugs. We deliver high-quality data in a fast turnaround time to help our customers select the most valuable drug candidates and initiate the clinical drug development process as soon as possible.

Why Kinases and Phosphatases Drugs?

Kinases and phosphatases are essential components of many biochemical cascades that are important for the amplification and dispersion of signals. These cascades allow networks to be created through interactions between different signaling pathways, thus providing opportunities for the integration of multiple inputs. It has been established through multiple lines of evidence that phosphorylation cascades are closely associated with the pathogenesis of diverse diseases such as cancer. Kinases and phosphatases have undoubtedly emerged as potential and interesting class of targets for the development of novel therapeutic agents. A number of potent and relatively selective inhibitors of kinases have been approved or undergoing clinical trials, however, much more projects are still at the preclinical stage of development. The safety and efficacy of drug candidates must be thoroughly evaluated before they are used in clinical trials. The development of kinase and phosphatase drugs still has a long way to go.

HZ-A-005, a potent, selective, and covalent Bruton’s tyrosine kinase inhibitor in preclinical development.

Figure 1. HZ-A-005, a potent, selective, and covalent Bruton's tyrosine kinase inhibitor in preclinical development. (Huang W, et al., 2020)

Overall Solutions

CD BioSicences provides comprehensive approaches and flexible solutions covering all the stages of preclinical drug development. Our well-established R&D laboratories, state-of-the-art equipment, and experienced scientific team enable us to handle all aspects of the process from protocol to final report. Turn your entire project over to us and we'll help speed up the entire drug development process.

  • Preclinical Safety Evaluation

    Drug candidates must undergo a rigorous preclinical safety evaluation to prevent side effects in clinical trials. Creative BioMart' team of pharmacologists and toxicologists is able to provide a full range of in vitro and in vivo testing, including but not limited to acute and repeated dose toxicity studies, genotoxicity studies, immunotoxicity studies, reproductive toxicity studies, and safety pharmacology studies. Preclinical safety evaluation will be conducted in the most efficient manner to move our customers' pipeline forward.

  • Preclinical Efficacy Evaluation

    Preclinical development should not only ensure that a drug candidate is safe but also effective. Creative BioMart provides both in vitro and in vivo models to fully evaluate preclinical efficacy and help our customers determine the most efficient drug candidates. Our scientists use their experience and expertise to select or establish animal disease models best suited to evaluate the efficacy of candidate kinase and phosphatase drugs and help our customers to predict their translational potential to humans.

  • Characterization of ADME Profile

    Understanding the absorption, distribution, metabolism, excretion (ADME) properties is essential for selecting drug candidates with desirable profiles suitable for clinical testing. Creative BioMart fully supports comprehensive ADME characterization backed up by a comprehensive portfolio of analytical techniques. We provide expert analysis and interpretation of ADME properties rather than just delivering experimental data. We stand ready to help strengthen your ability to achieve your preclinical goals.

  • Preclinical Formulation Development

    The majority of the small molecular kinase inhibitor drugs are limited by the low drug solubility and variable bioavailability. Creative BioMart provides customized preclinical formulation development solutions for small molecule drugs and therapeutic antibodies. Our formulation team helps our customers select the right formulation approach by thoroughly evaluating the physical and chemical properties of their drug candidates to address the solubility-related absorption and bioavailability issues.

Related Services

Creative BioMart is a trusted solution provider with many years of experience in kinase/phosphatase biology research and drug development. We have always been committed to providing our customers with high-quality products and customized services to accelerate their cutting-edge research and drug development pipeline. We fully support your project every step of the way to success.

Contact Us

Contact us to find out how our scientists can help you with your drug development project.


  • Huang W, et al. HZ-A-005, a potent, selective, and covalent Bruton's tyrosine kinase inhibitor in preclinical development. Bioorganic Chemistry, 2020, 105: 104377.
  • Brodniewicz T & Grynkiewicz G. Preclinical drug development. Acta Pol Pharm, 2010, 67(6): 578-585.
For research use only. Not intended for any clinical use.